Venusa Phomakay1, Mike Tankersley2,3. 1. Division of Allergy/Immunology, University of Tennessee Health Science Centers, Memphis, TN, USA. 2. Division of Allergy/Immunology, University of Tennessee Health Science Centers, Memphis, TN, USA. mtanker6@uthsc.edu. 3. The Tankersley Clinic, PLLC, Memphis, TN, USA. mtanker6@uthsc.edu.
Abstract
PURPOSE OF REVIEW: Allergen immunotherapy (AIT) has been shown to be safe and effective in children and is a unique treatment strategy that has disease-modifying and preventative effects that are not shared with other treatment options for allergic diseases. This article reviews the present knowledge and relevant updates on AIT in children. RECENT FINDINGS: Although there is no definite lower age limit for starting AIT, clear indications for AIT are established and each case should be considered individually by weighing risks and benefits. Documented short- and long-term benefits of AIT in children with allergic disease include significant improvement of symptoms and quality of life, and decreased use of medications as well as preventing the development of new allergen sensitizations and the progression of allergic rhinitis to asthma. This review provides a comprehensive overview of the present knowledge and key updates on AIT in the pediatric population.
PURPOSE OF REVIEW: Allergen immunotherapy (AIT) has been shown to be safe and effective in children and is a unique treatment strategy that has disease-modifying and preventative effects that are not shared with other treatment options for allergic diseases. This article reviews the present knowledge and relevant updates on AIT in children. RECENT FINDINGS: Although there is no definite lower age limit for starting AIT, clear indications for AIT are established and each case should be considered individually by weighing risks and benefits. Documented short- and long-term benefits of AIT in children with allergic disease include significant improvement of symptoms and quality of life, and decreased use of medications as well as preventing the development of new allergen sensitizations and the progression of allergic rhinitis to asthma. This review provides a comprehensive overview of the present knowledge and key updates on AIT in the pediatric population.
Authors: Linda Cox; Harold Nelson; Richard Lockey; Christopher Calabria; Thomas Chacko; Ira Finegold; Michael Nelson; Richard Weber; David I Bernstein; Joann Blessing-Moore; David A Khan; David M Lang; Richard A Nicklas; John Oppenheimer; Jay M Portnoy; Christopher Randolph; Diane E Schuller; Sheldon L Spector; Stephen Tilles; Dana Wallace Journal: J Allergy Clin Immunol Date: 2010-12-03 Impact factor: 10.793
Authors: Marek Jutel; Ioana Agache; Sergio Bonini; A Wesley Burks; Moises Calderon; Walter Canonica; Linda Cox; Pascal Demoly; Antony J Frew; Robin O'Hehir; Jörg Kleine-Tebbe; Antonella Muraro; Gideon Lack; Désirée Larenas; Michael Levin; Harald Nelson; Ruby Pawankar; Oliver Pfaar; Ronald van Ree; Hugh Sampson; Alexandra F Santos; George Du Toit; Thomas Werfel; Roy Gerth van Wijk; Luo Zhang; Cezmi A Akdis Journal: J Allergy Clin Immunol Date: 2015-07-07 Impact factor: 10.793